Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Retained Earnings (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Retained Earnings for 3 consecutive years, with -$330.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 256101.55% to -$330.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$330.5 million, a 256101.55% decrease, with the full-year FY2025 number at -$330.5 million, down 256101.55% from a year prior.
  • Retained Earnings was -$330.5 million for Q4 2025 at Artiva Biotherapeutics, down from $87000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $87000.0 in Q3 2025 to a low of -$330.5 million in Q4 2025.
  • A 3-year average of -$188.9 million and a median of -$221.9 million in 2024 define the central range for Retained Earnings.
  • Biggest YoY gain for Retained Earnings was 100.04% in 2025; the steepest drop was 256101.55% in 2025.
  • Artiva Biotherapeutics' Retained Earnings stood at -$181.3 million in 2023, then soared by 99.93% to -$129000.0 in 2024, then tumbled by 256101.55% to -$330.5 million in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Retained Earnings are -$330.5 million (Q4 2025), $87000.0 (Q3 2025), and -$288.2 million (Q2 2025).